Literature DB >> 7576106

Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors.

J P Packenham1, J A Taylor, C H Anna, C M White, T R Devereux.   

Abstract

Chromosome 9p21 appears to harbor a tumor suppressor gene, as evidenced by deletions in this region in a variety of human primary tumors and cell lines. To map the deletion at 9p21 in bladder tumors, we analyzed DNA from 28 tumor and normal pairs at five microsatellite markers that flank the region occupied by the putative tumor suppressor genes p16 and p15. Loss of heterozygosity (LOH) at the markers human interferon (HIFN) alpha and D9S171, which are adjacent to the p15 and p16 loci, was detected in 41% and 33%, respectively, of informative cases of bladder tumors. No sequence mutations were detected in exons 1 or 2 of either p15 or p16 in any of the bladder tumors. Three sequence-tagged site markers in the region bordered by HIFN alpha and D9S171 were used to further map the deleted region by multiplex polymerase chain reaction with the HIFN gamma maker (on chromosome 12) as a control for amplification. Six of 11 tumors with LOH at surrounding markers had homozygous deletions of the marker c5.1, which is located within the p16 gene; and two tumors appeared to have homozygous deletions within p15 (RN1.1) but not p16 (c5.1). A recently identified microsatellite marker, p16-CA-1, located 16 kb distal to p16, proved valuable in defining the minimal deletion involved in these bladder tumors. Five tumors exhibited homozygous deletions of this marker but not HIFN alpha and two tumors showed LOH at this marker and homozygous deletion of p16. Although these data could not be used to identify p16 or p15 as the definitive tumor suppressor gene in this region that is involved in bladder carcinogenesis, they suggest that homozygous deletion is a common mechanism of loss of tumor suppressor gene function in this region.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7576106     DOI: 10.1002/mc.2940140303

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  8 in total

1.  Microbeam MOMeNT: non-contact laser microdissection of membrane-mounted native tissue.

Authors:  M Böhm; I Wieland; K Schütze; H Rübben
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

2.  Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.

Authors:  Joanne S Aveyard; Margaret A Knowles
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

Review 3.  Molecular pathways in bladder cancer.

Authors:  Stephen G Williams; John P Stein
Journal:  Urol Res       Date:  2004-11-13

4.  G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder.

Authors:  G A Niehans; R A Kratzke; M K Froberg; D M Aeppli; P L Nguyen; J Geradts
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

5.  Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder.

Authors:  F Kimura; A R Florl; H H Seifert; J Louhelainen; S Maas; M A Knowles; W A Schulz
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

6.  p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.

Authors:  M A Le Frère-Belda; D Cappellen; A Daher; S Gil-Diez-de-Medina; F Besse; C C Abbou; J P Thiery; E S Zafrani; D K Chopin; F Radvanyi
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

7.  A high prevalence of functional inactivation by methylation modification of p16INK4A/CDKN2/MTS1 gene in primary urothelial cancers.

Authors:  T Akao; Y Kakehi; N Itoh; E Ozdemir; T Shimizu; A Tachibana; M S Sasaki; O Yoshida
Journal:  Jpn J Cancer Res       Date:  1997-11

8.  Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines.

Authors:  T Sørlie; G Martel-Planche; P Hainaut; J Lewalter; R Holm; A L Børresen-Dale; R Montesano
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.